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Evaluation of the efficacy and safety of terguride in patients with
fibromyalgia syndrome: Results of a twelve-week, multicenter,
randomized, double-blind, placebo-controlled, parallel-group
study
Abstract
OBJECTIVE: To assess the efficacy and safety of terguride, a partial dopamine agonist, in patients with
fibromyalgia syndrome (FMS). METHODS: In a 12-week, multicenter, double-blind,
placebo-controlled, parallel-group study, 99 patients were randomized at a ratio of 2 to 1 to receive
terguride or placebo. Over 21 days, the dosage was titrated to a maximum daily dose of 3 mg of
terguride or placebo, and this fixed dosage was continued over 9 weeks. The primary efficacy variable
was the intensity of pain (100-mm visual analog scale). Secondary efficacy variables included the
Fibromyalgia Impact Questionnaire (FIQ) score, the tender point score (TPS), and the Hamilton
Depression Scale (HDS) score. During the study, patients were evaluated for the presence of cervical
spine stenosis by magnetic resonance imaging (MRI). RESULTS: No significant differences in the
change in pain intensity, FIQ score, TPS, or HDS score between baseline and 12 weeks were observed
in the terguride group as compared with the placebo group. Cervical spine stenosis was detected in 22%
of the patients. Only patients with cervical spine stenosis responded to terguride treatment. FIQ scores
improved significantly (per-protocol analysis), and pain intensity, the TPS score, and the HDS score
showed a trend toward improvement in the terguride group as compared with the placebo group.
Terguride treatment was safe. Only those adverse events already known to be side effects of terguride
were observed. Premature termination of the study in patients receiving terguride (26%) occurred
predominantly during up-titration and in the absence of comedication for treatment of nausea.
CONCLUSION: Terguride treatment did not improve pain, the FIQ score, the TPS, or the HDS score in
the total study population. However, a subgroup of patients with cervical spine stenosis seemed to
benefit from terguride treatment.
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Abstract 
 
Objective: To assess the efficacy and safety of terguride, a partial dopamine agonist, in 
patients with fibromyalgia.  
Methods: In a 12 week multi-center, double-blind, placebo-controlled, parallel-group study 99 
patients were randomized 2:1 (terguride: placebo). They were up-titrated over 21 days to a 
maximum daily dose of 3 mg terguride or placebo and continued on fixed dose over 9 weeks. 
The primary efficacy variable was pain intensity on a 100-mm visual analog scale (VAS). 
Secondary efficacy variables included Fibromyalgia Impact Questionnaire (FIQ) score, tender 
point score (TPS) and Hamilton Depression Inventory (HAM-D). During the study, patients 
were assessed for the presence of cervical spinal stenosis (CSS) by magnetic resonance 
imaging (MRI).  
Results. No significant differences in changes of pain intensity, FIQ score, TPS and HAM-D 
score between baseline and at 12 weeks in the terguride and placebo group were observed. 
CSS was detected in 22 % of patients. Only patients with CSS responded to terguride 
treatment. FIQ scores improved significantly (per-protocol analysis) and pain intensity, TPS 
score and HAM-D showed a trend to improvement in the terguride group as compared to 
placebo. Terguride treatment was safe. Only adverse events (AEs) already known as side-
effects of terguride were observed. Premature termination of patients on terguride (29%) 
occurred predominantly during up-titration and in the absence of comedication for treatment 
of nausea.  
Conclusion. Terguride treatment did not improve pain, FIQ score, TPS or HAM-D score in 
the total study population. However, a subgroup of patients with CSS seems to benefit from 
terguride treatment.  
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INTRODUCTION 
 
Fibromyalgia (FMS) is a common yet poorly understood syndrome characterized by chronic 
widespread pain and tenderness to digital palpation of at least 11 of 18 defined tender points 
(1). Studies (2,3) have demonstrated that FMS patients experience pain differently from the 
general population and that dysfunctional pain processing plays a role. Central sensitization 
(3-5), dysfunction of inhibitory pathways (6,7) and altered neurotransmitter concentrations in 
the brain and the spinal cord (8-10) are discussed as pathomechanisms and as targets for 
therapeutic intervention.  
 
A central role of dopaminergic neurotransmission in modulating pain perception (10-13) was 
proposed. Dopaminergic neurons have been implicated in the control of perception of pain 
intensity (14), of anticipation and emotional response to pain (15), of stress response (11) as 
well as in spinal modulation of nociceptive input (16).  
 
The effects of the dopamine agonists pramipexole, ropinirole and rotigotine have or are been 
studied in FMS in prospective randomized clinical trials (17-19). In a 12-week trial in FMS 
patients receiving uncontrolled doses of concomitant medications that could effect FMS 
symptoms (17), dose titration of pramipexole resulted in significant improvements in pain, the 
Fibromyalgia Impact Questionnaire (FIQ) score and in distinct subscales of the 
Multidimensional Health Assessment Questionnaire. Based on these results, the evidence-
based recommendations for the management of FMS from the European League Against 
Rheumatism (EULAR) list pramipexole as “should be considered for treatment of FMS” (20), 
but emphasize the need for monotherapy trials without concomitant FMS medications for 
conclusive assessment of effect.  
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Here we report the results of a randomized, double-blind, placebo-controlled study of 
terguride in patients with primary fibromyalgia without relevant concomitant medical 
conditions and excluding concurrent FMS-targeted therapy. Terguride is a partial dopamine 
agonist and is approved as Teluron in Japan for the treatment of hyperprolactinemia (21,22). 
Since in the randomized, controlled trial of pramipexole FMS patients with comorbid cervical 
pain or compression were excluded, patients in this study were also assessed for CSS by 
magnetic resonance imaging (MRI) and possible differences in response to terguride were 
explored.  
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PATIENTS AND METHODS 
 
Entry criteria  
Patients were screened for eligibility about 6.6 days (range: 2-28 days) prior to treatment start. 
Eligible male or female patients met the following criteria: diagnosis of FMS according to the 
American College of Rheumatology (ACR) 1990 criteria (1), a pain score ≥50 mm on the 
patient-reported visual analog scale (VAS; 100 mm, (23)), a tender point score (TPS, (24)) 
≥11, age between 18 and 60 years, and a body mass index (BMI) between 18.9 and 30.0. 
Patients meeting the following criteria were excluded from the study: known sensitivity to 
terguride, suffering from relevant liver, kidney, cardiovascular or pulmonary disease, peptic 
ulcers, Raynaud`s phenomenon, psychosis, encephalomyelitis disseminata, chronic 
inflammatory diseases, a diagnosis of pituitary tumor representing extrasellar expansion, 
uncontrolled systolic blood pressure ≥140 mm Hg and a diastolic pressure ≥90 mm Hg, a 
history of drug or alcohol abuse, or mental impairment. Female patients, who had not used 
reliable contraception in the cycle before the study, who were pregnant or lactating were 
excluded. Patients on concurrent FMS-targeted therapy (i.e. antidepressants, selective 
serotonin reuptake inhibitors (SSRIs), antiepileptics, anxiolytics, muscle relaxants or 
hypnotics) were excluded, if they did not discontinue therapy at least 6 weeks prior to 
enrolment, or in the case of antiepileptics, anxiolytics, muscle relaxants or hypnotics 
discontinued medication ≥10 elimination half-lifes prior to enrolment. Constant treatment 
with non-steroidal anti-inflammatory drugs (NSAIDs) was allowed.  
 
Study design  
The study was carried out as a controlled trial at 1, 2 and 7 centers in Switzerland, the Czech 
Republic and Germany, respectively. The study protocol, amendments and consent forms 
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were approved by ethics committees and health authorities. A written informed consent was 
obtained from all patients at the time of enrolment. The trial was carried out in compliance 
with the Declaration of Helsinki. It was designed as a proof-of-concept study in the treatment 
of FMS with study medication over a period of 12 weeks. Active drug (0.5 mg terguride) and 
placebo were supplied as tablets with a subdividing breakmark. The study was conducted 
according to a randomized, double-blind, placebo-controlled, parallel-group design with a 2:1 
ratio of patients being treated with terguride or placebo, respectively. The study consisted of 
screening, a 3-week up-titration up to 6 tablets per day, a 9-week fixed dose treatment phase 
and a subsequent 5-day down-titration. Study medication was administered orally in the 
morning and in the evening. Treatment started (V0) with a half tablet in the evening and was 
increased after 3 days at constant dose by an additional half tablet in the morning. Thereafter, 
the daily dose was increased at 1 tablet increments every 3 days up to a maximum of 6 tablets 
after 21 days (V3). In case of insufficient tolerability, the dose increase could be modified. 
After Day 12, a dose increase could be postponed by 3 days in case of suspected drug-related 
adverse events (AEs). In case of reoccurrence of the AE, the dose increase was cancelled and 
the patient was maintained on a constant dose of ≥3 tablets throughout the study. Any patient, 
who did not tolerate 3 tablets per day left the study. From Day 22 until Day 84 (V12), the 
study medication remained at constant dose. Thereafter, patients were down-titrated over 5 
days (V13). Co-medications remained constant from 4 weeks prior to V0 and throughout the 
study.  
 
The primary efficacy variable was pain intensity as reported by the patient on the VAS (23). 
A standard deviation of pain VAS of 24 and a clinically relevant difference in mean change 
from baseline to V12 of the terguride group minus placebo of -17 mm was derived from 
Holman et al. (7). Assuming a one-sided significance level of 0.025 and a power of 80% at a 
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2:1 randomisation ratio in favor of active treatment a sample size of 72 patients (ITT-analysis) 
was obtained. Secondary efficacy variables were the differences in the Fibromyalgia Impact 
Questionnaire (FIQ) (25) score, the tender point score (TPS) (24) and the 17-point Hamilton 
Depression Scale (HAM-D) (26) score between treatment groups.  
 
Safety assessments consisted of monitoring all AEs and serious adverse events (SAEs). They 
included measurement of blood pressure and pulse rate, the performance of physical 
examinations including electrocardiography (ECG) and echocardiography, monitoring of 
hematological parameters, blood chemistry and urine analysis. Prolactin was quantified using 
routine assays.  
 
Oral administration of proton pump inhibitors (esomeprazol: ≤40mg/d; omeprazol: ≤40mg/d; 
panteprazol: ≤40mg/d) or up to 20 mg domperidone (a peripherally acting dopamine 
antagonist) 3 times per day was allowed on demand for treatment of nausea and was used by 
17 and 16 patients, respectively. In case of unbearable pain, patient could administer ≤2 g/d 
acetaminophen as rescue medication.  
 
MRI assessment  
A standardized protocol for neuroradiological assessment (including T1-w and T2-w sagittal 
and axial images) of the cervical spine on 1.5 Tesla MRI units was followed by all centers. 
Imaging was allowed at any time during the study. Midline sagittal views of the cervical 
spinal canal with the neck in neutral alignment were obtained. Centralized readings were 
performed by a blinded neuroradiologist (M.B.). Sagittal diameters of the spinal canal and the 
myelon were quantitated and spinal canal stenosis was graded according to modified criteria 
by Muhle et al. (27).  
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Statistical Analysis  
Statistical analyses were based on a safety, an intention-to-treat (ITT), and a per-protocol (PP) 
analysis set. The safety analysis set included all randomized subjects who received at least 
one dose of study medication. The ITT analysis set included all randomized subjects who 
received at least one dose of study medication and who provided a valid assessment of the 
primary variable at baseline and at least one post-baseline assessment. The PP analysis set 
excluded subjects with major protocol deviations and subjects who did not complete V12 for 
reasons definitely not related to study medication.  
 
Continuous variables were summarized by numbers of observations and arithmetic mean, 
standard deviation (SD), standard error mean (SEM) and 95% confidence interval (CI) or 
median, minimum, and maximum, respectively. Categorical data were described using 
absolute and relative frequencies. Efficacy was evaluated by comparing the absolute changes 
on pain VAS in the ITT analysis between treatment groups. The primary efficacy variable was 
evaluated by Analysis of Covariance (ANCOVA) using the baseline value as covariate. 
Analysis of secondary efficacy variables included descriptive summary statistics for FIQ 
scores and TPS at each time point. Categorical data were compared using the Fisher`s exact 
test. 
 
For the subgroup analysis patients with no or only partial obliteration of the anterior or 
posterior subarachnoid space of the cervical spine were allocated to one subgroup. Patients 
with myelon hyperintensity or cervical cord compression or displacement, were allocated to a 
second subgroup. The latter subgroup also included patients with complete obliteration of the 
subarachnoid space (grade 2) in the neutral position, which infers an increased probability of 
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functional relevant stenosis or worsening thereof, during flexion or extension (27) and can 
significantly impair function of the myelon. 
 
All efficacy analyses were performed in these two subgroups for exploratory purposes and p-
values < 0.05 were considered significant. 
 
The safety evaluations were based on the safety set by treatment groups and included analyses 
of AEs, safety laboratory measurements, physical examination, blood pressure and pulse rate, 
ECG, and echocardiogram. Safety data were evaluated by Fischer’s exact test.  
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RESULTS 
 
Characteristics of the study patients  
Between February 12, 2007 and February 1, 2008, a total of 118 patients were screened for 
participation in the study. Thereof, 99 patients were eligible for the study. They were enrolled 
and randomized to treatment with terguride (n = 65) or placebo (n = 34). All patients were of 
Caucasian race and 88 (88.9%) of the patients were female. 77 (77.8%) of the patients were 
between 41 and 55 years of age. No significant differences in gender, age, height, weight, 
body mass index (BMI), smoking habits and alcohol consumption between treatment groups 
were observed (Table 1). No significant differences in the baseline characteristics of the 
efficacy parameters between the terguride and placebo group were noted. 
 
The most frequently observed co-morbidities between the treatment groups were comparable. 
Ten patients had made prior use of opioids (5 patients) or anxiolytics (5 patients) or the 
combination of both (1 patient). In 6 patients (terguride: 4, placebo: 2) this was given for 
treatment of FMS. A single patient in the terguride group had a diagnosis of restless legs 
syndrome (RLS). Most frequently taken concomitant medications did not differ between 
treatment groups. Patients reported intake of NSAIDs/ anti-rheumatic drugs (terguride: 27 
(41.5%), placebo: 14 (41.2%)) or other analgesics and antipyretics (terguride: 21 (32.3%), 
placebo: 11 (32.4%)) for pain. Opioids were used “on demand” less than once per week, or 
during one treatment week in the midst of the treatment period only, by 2 patients (terguride: 
1, placebo: 1). Furthermore, 2 patients received opioids for a single day only during the 
treatment period (terguride: 1, placebo: 1). Six patients (terguride: 3, placebo: 3) and 1 patient 
were excluded from the ITT and PP data analysis due to ongoing daily intake of opioides or 
treatment with pramipexole during the up-titration phase for RLS, respectively. Six patients 
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received concomitantly 1.5 mg/d bromazepam (terguride: 5 (7.7%); placebo: 1 (2.9%)) and 5 
patients received 1 mg/d lormetazepam (terguride: 4 (6.2%); placebo: 1 (2.9%)) for the 
treatment of insomnia.  
 
An MRI was performed in a total of 78 patients (terguride: 51 (81.0%), placebo: 27 (79.4%)). 
21 patients did not consent to MRI. One patient was excluded due to failing the MRI protocol. 
When patients with intake of pramipexole or continuous treatment with opioides were 
excluded no or only partial obliteration of the anterior or posterior subarachnoid space was 
observed in 24 patients (terguride: 13, placebo: 11) and 33 patients (terguride: 25, placebo: 8), 
respectively (Table 2). A complete obliteration of the anterior or posterior subarachnoid space 
(grade 2), cervical cord compression or displacement (grade 3), or myelon hyperintensity 
(grade 4) was observed in 4 patients (terguride: 3, placebo: 1), 11 patients (terguride: 5, 
placebo: 6) and 1 patient (terguride: 0, placebo: 1), respectively. Only a single patient of the 
terguride group with grade 2 CSS received transiently during week 3 to 8 bromacepam for 
treatment of insomnia. No significant differences between treatment groups were observed. A 
spinal canal of <10 mm diameter at the C3/4, C4/5, C5/6, C6/7 and C7/Th1 level of the 
cervical spine was observed in 13.7%, 16.4%, 37.0%, 31.5% and 4.1% of the patients, 
respectively. No statistically significant differences in baseline efficacy parameters of the 
patient subgroups with or without CSS were observed.  
 
A total of 47 patients (72.3%) in the terguride group and 32 patients (94.1%) in the placebo 
group completed the study. Mean daily intake of study medication was 4.7 ± 0.20 (SEM) and 
5.5 ± 0.19 (SEM) tablets in the terguride and placebo groups, respectively. The study was 
prematurely terminated by 16 (24.6%) and 1 (2.9%) patient in the terguride and the placebo 
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group respectively, due to AEs. Furthermore, treatment of 1 patient each in the terguride and 
placebo group was terminated due to protocol violations. 
 
Efficacy 
In the total study population, pain intensity as the primary endpoint showed a mean change 
from baseline V0 to V12 (last observation carried forward (LOCF)) by -9 mm. This decrease in 
pain intensity (terguride: -9, CI: -14 to -4; placebo: -9, CI: -18 to -1) was not different 
between groups over the course of the study (p=0.971). The mean decrease in FIQ score from 
baseline to V12 (LOCF) was 8.2 in the study cohort. The mean decrease was more pronounced 
in the terguride (8.8, CI: 4.2 to 13.4) than in the placebo group (6.6, CI: 1.3 to 12.0), but was 
not significantly different between groups (p=0.221). The TPS and the number of positive 
tender points decreased from baseline to V12 (LOCF) by 3.5 and 0.8, respectively. The mean 
decrease in TPS score was slightly less pronounced in the terguride (3.3, CI: 1.4 to 5.2) than 
in the placebo group (4.4, CI: 0.6 to 8.2). There was no significant difference in the mean 
decrease of the tender point score (p= 0.703) or the total number of positive tender points 
(p= 0.377) between treatment groups. Furthermore, when patients were grouped according to 
response to therapy (Table 3), no significant differences between groups for pain VAS, FIQ 
score and TPS were observed. No treatment-related changes in the HAM-D score were 
observed during the course of the study between the terguride and placebo-treatment groups 
(p=0.937). 
 
Subgroup analysis 
In 57 patients with no or partial obliteration of the subarachnoid space of the cervical spine, 
no significant differences on pain VAS (-1 mm, CI: -12 to 9, p=0.795), FIQ score (-2.6, CI: -
11.6 to 6.5, p=0.572) and TPS (0.8, CI: -2.3 to 0.3, p=0.659) from baseline to V12 (LOCF) 
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between terguride treatment (N=38) and placebo (N=19) were observed. In contrast, a 
differential response to terguride was observed in patients (terguride: 8, placebo: 8) with CSS. 
Pain VAS, FIQ and TPS decreased more strongly under terguride when compared to placebo 
treatment (Figure 1). The differences in mean decrease of pain intensity (-10 mm, CI: -42 to 2, 
p=0.578), in FIQ score (-16.7, CI: -30.1 to 1.7, p=0.093) and in TPS (-10.9, CI:-23.8 to 2.0, 
p=0.087) from baseline to V12 (LOCF) between the terguride group and the placebo group 
were more pronounced in comparison to the respective patient groups without CSS in the ITT 
analysis. In the PP analysis effects of terguride treatment on FIQ-score in CSS patients (mean: 
-18.54, CI: -36.6 to -0.45, p=0.046) reached statistical significance. The pronounced effect on 
FIQ score by terguride versus placebo in the patient subgroup with grade 2-4 CSS was 
attributed predominantly to mean decreases of the physical impairment (-2.18, p=0.0328), do 
work (-1.88, p=0.0917), fatigue (-1.57, p=0.2359), rested (-1.48, p=0.3382), stiffness (-1.67, 
p=0.1288), anxiety (-3.66; p=0.0411) and depression (-2.33, p=0.132)subscales (Figure 2). 
 
Safety  
In total, 61 (93.8%) patients in the terguride group and 27 (79.4%) patients in the placebo 
group experienced at least one AE. AEs were predominantly of mild or moderate intensity. 
No patient experienced a SAE. Patients reported nausea (terguride: 21 (35.6%), placebo: 4 
(11.8%)), headache (terguride: 11 (18.6%), placebo: 9 (26.5%)) and insomnia (terguride: 
14 (23.7%), placebo: 3 (8.8%)) as the most frequent AEs (Figure 3). Nausea was noted at 
significantly higher frequency in the terguride group than in the placebo group (p<0.05). 
Other AEs including insomnia, upper abdominal pain, malaise, dyspepsia, vomiting, vertigo, 
abdominal pain and headache were not significantly different between treatment groups. A 
total of 21 (35.6%) patients in the terguride group and 6 (17.6%) patients in the placebo group 
experienced an AE which resulted in a dose reduction or which prevented a further dose 
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increase. Seventeen (28.8%) patients in the terguride group and 1 (2.9%) patient in the 
placebo group terminated prematurely the study due to nausea (terguride: 8 (13.6%), placebo: 
1 (2.9%)), vomiting (terguride: 4 (6.8%), placebo: 0) and dizziness (terguride: 3 (5.1%), 
placebo: 0). Premature termination occurred predominantly during dose up-titration. 
 
Vital signs, ECG parameters, physical examination and echocardiography did not indicate a 
significant effect of terguride on individual patients. There was no relevant change in 
laboratory safety parameters in the treatment groups. In agreement with its pharmacological 
mode of action, terguride treatment resulted in a lowering of prolactin serum levels (-3.1 µg/L 
prolactin, CI: -5.4 to -0.8) indicating that pharmacologically relevant concentrations of 
terguride have been achieved. No relevant change was observed in the placebo group 
(0.5 ug/L prolactin, CI: -1.2 to 2.2). 
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DISCUSSION 
 
Based on the dopaminergic hypothesis of FMS (28), we studied the therapeutic effects of 
terguride in FMS patients without other concurrent FMS-targeted drug therapy. Terguride was 
administered at or above dose levels, for which dopamine-agonistic action in Parkinson`s 
disease (29) and RLS (30) has been demonstrated. No significant differences in the primary 
endpoint reduction in VAS pain intensity between terguride treatment and placebo were 
observed. Similarly, secondary efficacy endpoints such as FIQ score, TPS and HAM-D score 
were not significantly different between terguride and placebo groups.  
 
Our findings are similar to the results of the study on safety and efficacy of the dopamine 
agonist ropinirole CR in FMS patients. This study is unpublished, but results are available 
from public repositories (19). No improvement in primary or secondary clinical endpoints was 
observed following ropinirole treatment as compared to placebo. Similarily, according to a 
recent press release on a Phase IIa study (NCT00464737) of the dopamine agonist rotigotine 
in FMS the primary endpoint reduction in pain during rotigotine treatment did not reach 
statistical significance when compared to a control group (31). In contrast, Holman and Myers 
(17) reported a significant therapeutic effect in FMS patients with concomitant medication by 
the dopamine agonist pramipexole.  
 
The apparent discrepancy of findings between the latter study and our study may be due to the 
differences in study populations, in trial designs and in the pharmacological profiles of the 
drugs used. For example, patients of the pramipexole trial received multiple comedications 
including narcotics, antiepileptics, antidepressants, SSRIs, anxiolytics, muscle relaxants or 
hypnotics making it difficult to accurately discern the therapeutic effect of the study drug. 
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This may reflect differences in patient populations, in practice patterns of clinicians in terms 
of number or types of drugs they provide to patients, or geographic difference in FMS 
treatment algorithms with drugs in off-label use.  Secondly, in the pramipexole study 
treatment groups, although not significantly different for individual drug classes, differed with 
respect to subgroups that received multiple FMS-targeted medications. Patients on dual drug 
therapy were more frequently allocated to the pramipexole group and a larger number of 
patients on quadruple therapy were reported in the placebo group. This may have favored an 
overall improved response in the pramipexole group. Thirdly, drug interactions, which 
potentiate analgesic effects such as interactions between opioids and dopamine agonists (32, 
33) may have contributed to an enhanced response to pramipexole as compared to placebo 
treatment. Finally, differences in the pharmacological profile of terguride and pramipexole 
must be considered. In contrast to pramipexole, which has an approximately 20-fold 
specificity for dopamine D3 over D2 receptors, terguride binds to these receptors with 
comparable affinity (34). Therefore, terguride may act on a differential subset of 
dopaminergic neurons when compared to pramipexole. Furthermore, terguride acts as a partial 
dopamine agonist, which implies that it preferably normalizes a deficit in dopamine receptor 
signaling rather than result in dopaminergic overstimulation. In contrast, pramipexole acts as a 
full agonist and an involvement of supra-physiological dopaminergic stimulation by 
pramipexole at high dosage in FMS patients may be considered.  
 
Patients of this study were recruited predominantly in rheumatology referral centers. They are 
regarded as a representative cross-section of FMS patients. An evaluation of the neurological 
status of patients was not performed in this study. However no apparent neurological findings 
were reported in the examinations at study entry or noted in the patients’ medical history. In 
21% of these patients, complete obliteration of the subarachnoid space, cervical cord 
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compression or displacement, or myelon hyperintensity was detected in a neutral position. 
Heffez et al. (35) reported CSS in 23% of a non-randomly selected FMS population, when the 
neck was positioned in extension and Holman et al (36) reported an abutment or compression 
of cervical spinal canal in 71% of his FMS population on cervical extension, but only in 29% 
in neutral position. The studies emphasize that despite apparently normal appearance of the 
cervical central spinal canal in neutral view, significant stenosis and intermittent functional 
impairment does occur with cervical spinal motion. Clauw et al. (37) reported a 50% 
prevalence of CSS in a FMS cohort, but no difference in prevalence of CSS in FMS patients 
and matched healthy subjects. Therefore, a direct causal relationship between CSS and FMS 
remains unlikely. Nevertheless, irritation at the spinal level (38) or altered spinal nociceptive 
processing (39) may exaggerate FMS symptoms. Patients meeting diagnostic ACR-criteria of 
FMS and having concomitant CSS may represent a form of secondary FMS with possibly 
differential symptoms (40) and responding differently to therapy.  
 
Of note, when analysing the results of this study it needs to be taken into account that only 16 
patients with grade 2-4 CSS were identified by MRI and that the assessment of therapeutic 
effects is based on small group sizes. Nevertheless and despite the large variability in patient 
oriented scores, a significant decrease of the FIQ score was observed including effects on 
physical impairment, do work, rested, stiffness, anxiety and depression subscales.  
 
The pathophysiology of spinal stenosis is still under discussion. Besides static factors that lead 
to canal encroachment, including congenitally narrowed canal, disk bulging, and spondylitic 
osteophytes, alteration in the spinal vasculature appears to play a role (41). Drug treatment of 
spinal stenosis is so far predominantly of symptomatic nature, but therapeutic effects of 
prostaglandin E1 in patients with lumbar spinal stenosis (42) were recently reported. 
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Furthermore, promising effects of the 5-HT2A antagonist sarpogrelate have been observed in 
patients (43) and animal models of disc herniation or experimentally-induced spinal stenosis 
(44, 45). Terguride, in addition to being a dopamine agonist, also acts as a high affinity 
antagonist on 5-HT2 receptors as well as a α2-adrenolytic agent in functional bioassays (46). 
Thus 5-HT2 antagonism might provide a potential explanation for the therapeutic effects of 
terguride in patients with CSS.  
In this study only AEs already known as side-effects of terguride were observed. They 
occurred predominantly and transiently during up-titration of terguride. As known from 
previous clinical experience and as expected for this drug class, nausea was noted as the most 
frequent terguride-related AE. Premature termination of patients on terguride treatment was 
observed with nausea, vomiting and dizziness being named as the most frequent causes. The 
drop-out rate in the terguride group was 26% as compared to 3% in the placebo group. Rather 
rapid dose escalation, lack of co-medication for control of gastrointestinal side effects in 10 
out of 14 drop-outs, and a generally increased sensitivity of FMS patients to AEs of drugs 
may have contributed hereto. In clinical use peripheral-acting dopamine antagonists (47, 48) 
are highly effective in improving the tolerability of dopamine agonists without interference of 
therapeutic effects. Indeed, most patients, who received either domperidon or proton pump 
inhibitors as co-medication for nausea, completed the study on schedule.  
In this study, an increased frequency of insomnia and use of bromazepam or lormetazepam 
for treatment of insomnia in the terguride treatment group was observed, although there was 
no significant difference between the treatment groups. The profile of terguride differs in this 
respect from other dopamine agonists, for which an increased prevalence of sleep attacks (49) 
in patients with Parkinson`s disease has been noted and which remain a matter of concern in 
the use of dopamine agonists.  
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In summary, terguride treatment did not improve pain, FMS intensity or HAM-D score in the 
total study population. However, a subgroup of patients with CSS seems to benefit from 
terguride treatment and warrants further studies. 
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Tables  
 
Table 1: Demographic characteristics of study population and efficacy parameters at baseline 
 
  All patients 
N=99 
Terguride 
N=65 
Placebo 
N=34 
p-value 
  N % N % N %  
Ethnic group Caucasian 99 100 65 100 34 100  
Female 88 88.9 58 89.2 30 88.2 Gender 
Male 11 11.1 7 10.8 4 11.8 
 
1.000 
Total 
population 
48.7±6.4  48.5±6.1  49.0±7.0  
26-30 1 1.0 - - 1 2.9 
31-35 4 4.0 3 4.6 1 2.9 
36-40 5 5.1 4 6.2 1 2.9 
41-45 21 21.2 13 20.0 8 23.5 
46-50 26 26.3 20 30.8 6 17.6 
51-55 30 30.3 17 26.2 13 38.2 
Age [years] 
56-60 12 12.1 8 12.3 4 11.8 
0.702 
Height [cm]  165.8±7.5  165.4±7.6  166.5±7.3  0.496 
Weight [kg]  70.3±10.3  70.9±11.1  69.2±8.7  0.440 
BMI [kg/m2]  25.6±3.2  25.9±3.3  25.0±3.0  0.203 
Non-smoker 55 55.6 36 55.4 19 55.9 
Former 
smoker 
16 16.2 9 13.8 7 20.6 
Smoking 
habits 
Active 
smoker 
28 28.3 20 30.8 8 23.5 
 
 
 
 
0.594 
Almost 
abstinent 
67 67.7 45 69.2 22 64.7 Alcohol 
Consumption 
Moderate $ 32 32.3 20 30.8 12 35.3 
 
 
0.648 
Efficacy parameters at 
baseline 
       
VAS pain [mm] 71.3±15.6   70.8±16.7  72.2±13.5   
0.687 
            Male (N=11) 70.2±15.1  70.1±15.3  70.3±17.0   
0.992 
            Female (N=86) 71.4±15.8  70.9±17.0  72.4±13.3   
0.671 
FIQ score 59.2±16.4  59.3±16.7  59.1±16.0   
0.957 
Tender point score 38.2±10.1  38.3±10.6  38.2±9.4   
0.980 
Number of tender points 16.4 ± 1.7  16.4 ± 1.7  16.5 ± 1.7  0.657 
HAM-D 17 score * 14.2 ± 7.3  14.2 ± 7.0  14.1± 8.1  0.979 
 
$
 moderate alcohol consumption as defined by  ≤ 16 g alcohol/d for women and ≤ 24 g alcohol/d 
for men). Data on height, weight, BMI and efficacy parameters are given as mean ± standard 
deviation. * N=70 (terguride: 46; placebo: 24). Statistical significance of differences between 
treatment groups are indicated by p values as calculated byANOVA model using treatment 
group as factor.  
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Table 2: Mean sagittal diameter of spinal canal and myelon, and frequency distribution of spinal stenosis grading by cervical segments. 
 
 Spinal canal 
diameter  
Myelon 
diameter   
Spinal canal 
diameter < 10 mm 
Cervical Spinal Stenosis Grade 
Segment [mm] [mm] N {%} 0 1 2 3 4 
C1/C2  14.4 (14.1-14.7)      7.9 (7.8-8.1)          0 {  0} 73 - - - - 
C2/C3  12.7 (12.4-13.0)      7.7 (7.6-7.8)          3 {  4.1} 73 - - - - 
C3/C4  11.6 (11.2-12.0)      7.5 (7.4-7.6)        10 {13.7} 65 6 - 2 - 
C4/C5  11.1 (10.7-11.5)      7.3 (7.2-7.4)        12 {16.4} 57 13 1 2 - 
C5/C6  10.3 (  9.8-10.8)      7.0 (6.9-7.1)        27 {37.0} 36 26 3 7 1 
C6/C7  10.7 (10.3-11.2)      6.8 (6.7-6.9)        23 {31.5} 44 19 7 3 - 
C7/Th1  12.0 (11.7-12.3)      6.7 (6.6-6.8)          3 {  4.1} 73 - - - - 
Spinal stenosis grading       
         All patients (73)* 24 33 4 11 1 
         Terguride (N=50)  13 25 3 5 - 
         Placebo (27) 11 8 1 6 1 
         Statistical significance (p-value)  0.164 
 
Data on are means. In parenthesis 95% confidence intervals are given.  
Patients with intake of pramipexole or continuous treatment with opioids were excluded from analysis.  
    * A diagnosis was not available from 30 patients (terguride: 13; placebo: 7)  
                            Statistical significance of difference between treatment groups are indicated by p value as calculated by Chi-square test 
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Table 3: Response in pain VAS, FIQ or TPS to study medication: Change from baseline V0 to V12 
(LOCF)   
 
 
 
Patients with intake of pramipexole or continuous treatment with opioides were excluded 
from analysis  
Chi-square test:  
Statistical significance of difference between treatment groups are indicated by p value as 
calculated by Chi-square test (*: excluded from statistical analysis) 
 Terguride (N=59) Placebo (N=31) p-value 
Pain VAS N % N % 0.830 
≥ 50% improvement 10 16.9 6 19.4  
≥ 20% and < 50% 
improvement 
10 
 
16.9 3 9.7  
change within ± 20%  30 50.8 17 54.8  
≥ 20% worsening 9 15.3 5 16.1  
FIQ score     0.516 
≥ 50% improvement 9 15.3 3 9.7  
≥ 20% and < 50% 
improvement 
11 18.6 3 9.7  
change within ± 20%  33 55.9 22 71.0  
≥ 20% worsening 6 10.2 3 9.7  
TPS     0.300 
≥ 50% improvement 4 6.8 0 0  
≥ 20% and < 50% 
improvement 
9 15.3 6 19.4  
change within ± 20%  44 74.6 23 74.2  
≥ 20% worsening 1 1.7 2 6.5  
Not quantifiable* 1 1.7 0 0.0  
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Figure Legends:  
 
Figure 1:  Time course of mean VAS pain intensity, FIQ score and TPS in terguride and placebo-
treated patient subgroups.  Boxes: Patients with Grade 0-1 cervical spinal stenosis (56, terguride: 37, 
placebo: 19). Circles: Patients with Grade 2-4 cervical spinal stenosis (15, terguride: 7, placebo: 8). 
Open and closed symbols are means of placebo-treated or terguride-treated patients, respectively.  
 
Figure2: Absolute change from baseline of FIQ subscales in terguride and placebo-treated patients. 
Boxes: Patients with Grade 0-1 cervical spinal stenosis (56: terguride: 38, placebo: 18).  
Circles: Patients with Grade 2-4 cervical spinal stenosis (15: terguride: 7, placebo: 8).  
Open and closed symbols are means of placebo-treated or terguride-treated patients, respectively. Data 
are mean ± SEM. (*: p<0.05) 
 
Figure 3: Frequencies of treatment-emerging adverse events in terguride and placebo-treated 
patients. Open bars: placebo group, Closed bars: terguride treatment group. Frequencies are 
given as percentage of patients with at least one treatment emerging adverse events. (*: p< 
0.05) 
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Figures 
 
Figure 1:  
 
 
0 4 8 12
2
4
6
8
10
Pa
in
 
VA
S 
[cm
]
0 4 8 12
20
40
60
80
FI
Q-
G
 
Sc
o
re
 
0 4 8 12
Time [weeks]
20
40
60
80
Te
n
de
r 
Po
in
t S
co
re
 
A
B
C
p=0.477
p=0.046
p=0.665
p=0.104
p=0.743
p=0.321
 
 
P
ag
e
 33
 of
 37
 
 Fig
u
re
 2
:
 
 
  
Physical impairment
Feel good
Work missed
Do work
Pain
Fatigue
Rested
Stiffness
Anxiety
Depression
-5 -4 -3 -2 -1 0 1 2
Absolute Change from
Baseline  
Physical impairment
Feel good
Work missed
Do work
Pain
Fatigue
Rested
Stiffness
Anxiety
Depression
-5 -4 -3 -2 -1 0 1 2
Absolute Change from
Baseline
AB
*
*
 
  
 
P
ag
e
 34
 of
 37
 
 Fig
u
re
 3
 
  
Nausea
Headache
Insomnia
Constipation
Fatigue
Upper abdominal pain
Malaise
Dizziness
Dyspepsia
Vomitting
Nasopharyngitis
Vertigo
Abdominal pain
Depression
Diarrhoe
Fibromyalgia
Flatulence
Hyperhidrosis
Pain
Sleeping disorder
0 10 20 30 40
Frequency of  Adverse
Events [% of patients] 
*
    
 Page 35 of 37 
 
 
Figures according to specifications ( width ≤ 8.4 cm, height: ≤21.5 cm) 
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Figure 1: Time course of mean VAS pain  intensity, FIQ score and  TPS 
in terguride and placebo-treated patient subgroups. Boxes: Patients  with 
Grade 0-1  cervical  spinal  stenosis (56, terguride: 37, placebo: 19).  
Circles: Patients with Grade 2-4 cervical spinal stenosis (15, terguride: 7, 
placebo: 8). Open and closed  symbols  are  means of  placebo-treated or 
terguride-treated patients, respectively.  
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Figure 2: Absolute  change from baseline of FIQ subscales  in  terguride 
treated  and  placebo-treated  patients.  Boxes:  Patients  with Grade  0-1 
cervical spinal stenosis (56: terguride: 38, placebo: 18). Circles: Patients 
with Grade 2-4 cervical spinal stenosis (N=15: terguride: 7, placebo: 8).  
Open and closed  symbols  are  means  of  placebo-treated  or  terguride- 
treated patients, respectively. Data are mean ± SEM. (*: p<0.05) 
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Figure 3: Frequencies  of  treatment-emerging adverse events in terguride 
treated and  placebo-treated  patients. Open  bars:  placebo  group, Closed 
bars: terguride treatment group. Frequencies are  given  as  percentage  of 
patients with at least one treatment emerging adverse events. (*: p< 0.05) 
 
